Applied Therapeutics, Inc. (APLT)
Stock Price:
$22.29 USD
-1.17 (-4.99%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
500.09M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-68.77M |
| Shares Out |
22.44M |
| EPS (ttm) |
-3.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$22.29 |
| Previous Close |
$23.46 |
| Change ($) |
-1.17 |
| Change (%) |
-4.99% |
| Day's Open |
23.61 |
| Day's Range |
22.08 - 23.73 |
| Day's Volume |
71,315 |
| 52-Week Range |
10.75 - 57.39 |
More Stats
| Market Cap |
500.09M |
| Enterprise Value |
363.45M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.44M |
| Float |
13.08M |
| EPS (basic) |
-4.06 |
| EPS (diluted) |
-3.68 |
| FCF / Share |
-2.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.61M |
| Short Ratio |
11.02 |
| Short % of Float |
12.35% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.04 |
| Revenue |
n/a |
| Operating Income |
-69.16M |
| Net Income |
-68.77M |
| Free Cash Flow |
-55.01M |
| Net Cash |
136.63M |
| Net Cash / Share |
6.09 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-44.19% |
| ROE |
-80.81% |
| ROIC |
-203.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$60.50*
(171.42% upside)
Low
42.0
Current: $22.29
High
85.0
Target: 60.50
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -45.58 | -13.52 | -4.29 |
| Net Income | -45.51 | -16.52 | -4.28 |
| Shares Outstanding | 12.83 | 5.48 | 5.41 |
| Earnings Per Share | -3.55 | -3.01 | -0.79 |
| Operating Cash Flow | -36.31 | -11.18 | -3.20 |
| Free Cash Flow | -36.31 | -11.18 | -3.20 |
| Cash & Equivalents | 38.85 | 18.75 | 3.28 |
| Total Debt | 2.04 | - | - |
| Net Cash / Debt | 36.82 | 18.75 | 3.28 |
| Assets | 48.39 | 20.25 | 3.29 |
| Liabilities | 15.78 | 4.43 | 0.99 |
| Book Value | 32.61 | -19.59 | -3.96 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Applied Therapeutics, Inc. |
| Country |
United States |
| Employees |
18 |
| CEO |
Shoshana Shendelman |
Stock Information
| Ticker Symbol |
APLT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: APLT |
| IPO Date |
May 14, 2019 |
Description
Applied Therapeutics, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.